Stockreport

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder [Yahoo! Finance]

Cybin Inc.  (HELP) 
PDF Helus Pharma Statistically significant (pCare (“SoC”) at 6 weeks Durable effects sustained through at least 6 months In Phase 1 trial most participants were ready [Read more]